Tivic Health Partners with NIAID to Evaluate Entolimod for Radiation Syndrome

Key Facts

Tivic Health Systems (Nasdaq: TIVC) has entered into a non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases (NIAID). The collaboration focuses on conducting preclinical studies to evaluate the drug candidate Entolimod as a medical countermeasure. Specifically, the studies aim to assess the drug's efficacy in treating gastrointestinal acute radiation syndrome (GI-ARS). The research will be conducted by the Armed Forces Radiobiology Research Institute (AFRRI) under the sponsorship of the NIAID. This partnership provides Tivic Health with significant government-backed resources and validation for its lead candidate. While the drug remains in the preclinical stage, the agreement marks a critical milestone in the company's clinical development strategy.